Terms: = Breast cancer AND JAK1, ENSG00000162434, P23458, JTK3, JAK1B, JAK1A, 3716
116 results:
1. Withaferin A alters the expression of microRNAs 146a-5p and 34a-5p and associated hub genes in MDA-MB-231 cells.
Shuaib M; Chaudhri S; Kumar S
Biomol Concepts; 2024 Jan; 15(1):. PubMed ID: 38525814
[TBL] [Abstract] [Full Text] [Related]
2.
Li F; Wu Y; Shi Y; Liu X; Xie Y; Liu S
Acta Biochim Biophys Sin (Shanghai); 2024 Mar; 56(3):462-473. PubMed ID: 38379418
[TBL] [Abstract] [Full Text] [Related]
3. Combined effects of naringin and doxorubicin on the JAK/STAT signaling pathway reduce the development and spread of breast cancer cells.
Effat H; Abosharaf HA; Radwan AM
Sci Rep; 2024 Feb; 14(1):2824. PubMed ID: 38310190
[TBL] [Abstract] [Full Text] [Related]
4. TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer.
Lynce F; Stevens LE; Li Z; Brock JE; Gulvady A; Huang Y; Nakhlis F; Patel A; Force JM; Haddad TC; Ueno N; Stearns V; Wolff AC; Clark AS; Bellon JR; Richardson ET; Balko JM; Krop IE; Winer EP; Lange P; Hwang ES; King TA; Tolaney SM; Thompson A; Gupta GP; Mittendorf EA; Regan MM; Overmoyer B; Polyak K
Breast Cancer Res; 2024 Jan; 26(1):20. PubMed ID: 38297352
[TBL] [Abstract] [Full Text] [Related]
5. Molecular Mechanism Analysis of Protopine Against Triple Negative breast cancer.
Chen T; Jiang H; Hu G; Acma FM; Huang B
Stud Health Technol Inform; 2023 Nov; 308():480-486. PubMed ID: 38007774
[TBL] [Abstract] [Full Text] [Related]
6. [Hsa-miR-148a-3p promotes malignant behavior of breast cancer cells by downregulating DUSP1].
Xu J; Lin L; Chen Q; Li L
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Sep; 43(9):1515-1524. PubMed ID: 37814866
[TBL] [Abstract] [Full Text] [Related]
7. Discovery of Novel Fedratinib-Based HDAC/JAK/BRD4 Triple Inhibitors with Remarkable Antitumor Activity against Triple Negative breast cancer.
Zhao C; Zhang Y; Zhang J; Li S; Liu M; Geng Y; Liu F; Chai Q; Meng H; Li M; Li J; Zheng Y; Zhang Y
J Med Chem; 2023 Oct; 66(20):14150-14174. PubMed ID: 37796543
[TBL] [Abstract] [Full Text] [Related]
8. RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive breast cancer and Beyond.
Wu J; Subbiah V
Cancer Res; 2023 Oct; 83(19):3159-3161. PubMed ID: 37779428
[TBL] [Abstract] [Full Text] [Related]
9. SKAP1 Is a Novel Biomarker and Therapeutic Target for Gastric cancer: Evidence from Expression, Functional, and Bioinformatic Analyses.
Zhu L; Yu Q; Li Y; Zhang M; Peng Z; Wang S; Quan Z; Gao D
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511629
[TBL] [Abstract] [Full Text] [Related]
10. High expression of STAT3 within the tumour-associated stroma predicts poor outcome in breast cancer patients.
Morrow E; Pennel K; Hatthakarnkul P; Leslie H; Mallon E; Andersen D; Jamieson N; McMillan D; Roseweir A; Edwards J
Cancer Med; 2023 Jun; 12(12):13225-13240. PubMed ID: 37199043
[TBL] [Abstract] [Full Text] [Related]
11. Mammary-like adenocarcinoma of the vulva: a rare case report with next generation sequencing.
Lobrano R; Manca A; Sini MC; Palmieri G; Petrillo M; Cossu A; Paliogiannis P
Pathologica; 2023 Apr; 115(2):101-106. PubMed ID: 37114627
[TBL] [Abstract] [Full Text] [Related]
12. CXCL9 influences the tumor immune microenvironment by stimulating JAK/STAT pathway in triple-negative breast cancer.
Wu L; Sun S; Qu F; Sun M; Liu X; Sun Q; Cheng L; Zheng Y; Su G
Cancer Immunol Immunother; 2023 Jun; 72(6):1479-1492. PubMed ID: 36472587
[TBL] [Abstract] [Full Text] [Related]
13. Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative breast cancer.
Peng P; Qiang X; Li G; Li L; Ni S; Yu Q; Sourd L; Marangoni E; Hu C; Wang D; Wu D; Wu F
Mol Cancer Ther; 2023 Feb; 22(2):205-214. PubMed ID: 36223547
[TBL] [Abstract] [Full Text] [Related]
14. Identification of novel piperazine-tethered phthalazines as selective CDK1 inhibitors endowed with in vitro anticancer activity toward the pancreatic cancer.
Akl L; Abd El-Hafeez AA; Ibrahim TM; Salem R; Marzouk HMM; El-Domany RA; Ghosh P; Eldehna WM; Abou-Seri SM
Eur J Med Chem; 2022 Dec; 243():114704. PubMed ID: 36095992
[TBL] [Abstract] [Full Text] [Related]
15. Her2/EGFR-PDGFR pathway aberrations associated with tamoxifen response in metastatic breast cancer patients.
Malash I; Mansour O; Gaafar R; Shaarawy S; Abdellateif MS; Ahmed OS; Zekri AN; Bahnassy A
J Egypt Natl Canc Inst; 2022 Jul; 34(1):31. PubMed ID: 35871690
[TBL] [Abstract] [Full Text] [Related]
16. FRZB is Regulated by the Transcription Factor EGR1 and Inhibits the Growth and Invasion of Triple-Negative breast cancer Cells by Regulating the JAK/STAT3 Pathway.
Liu H; Mei Y; Ma X; Zhang X; Nie W
Clin Breast Cancer; 2022 Oct; 22(7):690-698. PubMed ID: 35787980
[TBL] [Abstract] [Full Text] [Related]
17. DPYSL2 interacts with jak1 to mediate breast cancer cell migration.
Abu Rmaileh A; Solaimuthu B; Khatib A; Lavi S; Tanna M; Hayashi A; Ben Yosef M; Lichtenstein M; Pillar N; Shaul YD
J Cell Biol; 2022 Jul; 221(7):. PubMed ID: 35575798
[TBL] [Abstract] [Full Text] [Related]
18. Identification of a combined apoptosis and hypoxia gene signature for predicting prognosis and immune infiltration in breast cancer.
Ren X; Cui H; Wu J; Zhou R; Wang N; Liu D; Xie X; Zhang H; Liu D; Ma X; Dang C; Kang H; Lin S
Cancer Med; 2022 Oct; 11(20):3886-3901. PubMed ID: 35441810
[TBL] [Abstract] [Full Text] [Related]
19. Evaluation of the Effect of Abrocitinib on Drug Transporters by Integrated Use of Probe Drugs and Endogenous Biomarkers.
Vourvahis M; Byon W; Chang C; Le V; Diehl A; Graham D; Tripathy S; Raha N; Luo L; Mathialagan S; Dowty M; Rodrigues AD; Malhotra B
Clin Pharmacol Ther; 2022 Sep; 112(3):665-675. PubMed ID: 35344588
[TBL] [Abstract] [Full Text] [Related]
20. Measured body size and serum estrogen metabolism in postmenopausal women: the Ghana breast Health Study.
Geczik AM; Falk RT; Xu X; Ansong D; Yarney J; Wiafe-Addai B; Edusei L; Dedey F; Vanderpuye V; Titiloye N; Adjei E; Aitpillah F; Osei-Bonsu E; Oppong J; Biritwum R; Nyarko K; Wiafe S; Awuah B; Clegg-Lamptey JN; Ahearn TU; Figueroa J; Garcia-Closas M; Brinton LA; Trabert B
Breast Cancer Res; 2022 Jan; 24(1):9. PubMed ID: 35081987
[TBL] [Abstract] [Full Text] [Related]
[Next]
